Literature DB >> 9665427

Simultaneous determination of mycophenolic acid and its glucuronide in human plasma using a simple high-performance liquid chromatography procedure.

M Shipkova1, P D Niedmann, V W Armstrong, E Schütz, E Wieland, L M Shaw, M Oellerich.   

Abstract

We describe a reversed-phase HPLC method for determination of total mycophenolic acid (MPA), its free concentration (MPAf), and the glucuronide metabolite (MPAG), based on simple sample preparation and gradient elution chromatography. The compounds were quantified in parallel by absorbance at 254 nm and 215 nm in the internal standard mode. Linearity was verified up to 50 mg/L for MPA and up to 500 mg/L for MPAG (r >0.999). Detection limits at 215 and 254 nm were, respectively, 0.01 and 0.03 mg/L for MPA, and 0.03 and 0.1 mg/L for MPAG. The recovery of MPA was 95-106%; recovery of MPAG was 96-106%. The imprecision (CV) for MPA (0.2-25 mg/L) was <8.4% (254 nm) and <4.4% (215 nm) within day (n = 12) and <9.2% (254 nm) and <6.2% (215 nm) between days (n = 12). The imprecision for MPAG (10-250 mg/L) was <4.9% (254 nm) and <3.4% (215 nm) within day, and <6.1% (254 nm) and <5.9% (215 nm) between days. For quantification of MPAf, 100 microL of ultrafiltrate was applied directly to the column. The detection limit was 0.005 mg/L at 215 nm and 0.015 mg/L at 254 nm. In the range between 18-210 microg/L, the within-day CVs were <11.8% (n = 12) and the between-day CVs were <15.8% (n = 12).

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9665427

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  12 in total

1.  Development of population PK model with enterohepatic circulation for mycophenolic acid in patients with childhood-onset systemic lupus erythematosus.

Authors:  Catherine M T Sherwin; Anna Carmela P Sagcal-Gironella; Tsuyoshi Fukuda; Hermine I Brunner; Alexander A Vinks
Journal:  Br J Clin Pharmacol       Date:  2012-05       Impact factor: 4.335

2.  Identification of glucoside and carboxyl-linked glucuronide conjugates of mycophenolic acid in plasma of transplant recipients treated with mycophenolate mofetil.

Authors:  M Shipkova; V W Armstrong; E Wieland; P D Niedmann; E Schütz; G Brenner-Weiss; M Voihsel; F Braun; M Oellerich
Journal:  Br J Pharmacol       Date:  1999-03       Impact factor: 8.739

Review 3.  Enteric-coated mycophenolate sodium: tolerability profile compared with mycophenolate mofetil.

Authors:  Matthias Behrend; Felix Braun
Journal:  Drugs       Date:  2005       Impact factor: 9.546

4.  Associations of UDP-glucuronosyltransferases polymorphisms with mycophenolate mofetil pharmacokinetics in Chinese renal transplant patients.

Authors:  Xiao-chun Xie; Jun Li; Hong-yang Wang; Hong-liang Li; Jing Liu; Qian Fu; Jia-wen Huang; Chen Zhu; Guo-ping Zhong; Xue-ding Wang; Ping-ping Sun; Min Huang; Chang-xi Wang; Jia-li Li
Journal:  Acta Pharmacol Sin       Date:  2015-04-13       Impact factor: 6.150

5.  Inosine monophosphate dehydrogenase (IMPDH) activity as a pharmacodynamic biomarker of mycophenolic acid effects in pediatric kidney transplant recipients.

Authors:  Tsuyoshi Fukuda; Jens Goebel; Håvard Thøgersen; Denise Maseck; Shareen Cox; Barbara Logan; Joseph Sherbotie; Mouin Seikaly; Alexander A Vinks
Journal:  J Clin Pharmacol       Date:  2010-04-23       Impact factor: 3.126

6.  Inosine monophosphate dehydrogenase variability in renal transplant patients on long-term mycophenolate mofetil therapy.

Authors:  Laurent R Chiarelli; Mariadelfina Molinaro; Carmelo Libetta; Carmine Tinelli; Laura Cosmai; Giovanna Valentini; Antonio Dal Canton; Mario Regazzi
Journal:  Br J Clin Pharmacol       Date:  2010-01       Impact factor: 4.335

7.  Pharmacokinetics of mycophenolic acid, tacrolimus and sirolimus after gastric bypass surgery in end-stage renal disease and transplant patients: a pilot study.

Authors:  Christin C Rogers; Rita R Alloway; J Wesley Alexander; Michael Cardi; Jennifer Trofe; Alexander A Vinks
Journal:  Clin Transplant       Date:  2008 May-Jun       Impact factor: 2.863

8.  Effects of unbound mycophenolic acid on inosine monophosphate dehydrogenase inhibition in pediatric kidney transplant patients.

Authors:  Thomas A Smits; Shareen Cox; Tsuyoshi Fukuda; Joseph R Sherbotie; Robert M Ward; Jens Goebel; Alexander A Vinks
Journal:  Ther Drug Monit       Date:  2014-12       Impact factor: 3.681

9.  UGT1A9, UGT2B7, and MRP2 genotypes can predict mycophenolic acid pharmacokinetic variability in pediatric kidney transplant recipients.

Authors:  Tsuyoshi Fukuda; Jens Goebel; Shareen Cox; Denise Maseck; Kejian Zhang; Joseph R Sherbotie; Eileen N Ellis; Laura P James; Robert M Ward; Alexander A Vinks
Journal:  Ther Drug Monit       Date:  2012-12       Impact factor: 3.681

10.  Spectrophotometric Determination of Mycophenolate Mofetil as Its Charge-Transfer Complexes with Two π-Acceptors.

Authors:  K B Vinay; H D Revanasiddappa; M S Raghu; Sameer A M Abdulrahman; N Rajendraprasad
Journal:  J Anal Methods Chem       Date:  2012-03-26       Impact factor: 2.193

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.